The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Fabry Disease Therapeutic-Global Market Insights and Sales Trends 2025
Synopsis
The global Fabry Disease Therapeutic market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fabry Disease Therapeutic in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Fabry Disease Therapeutic market. Enzyme Replacement Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Alternative therapies segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Fabry Disease Therapeutic, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Fabry Disease Therapeutic market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Fabry Disease Therapeutic market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Fabry Disease Therapeutic sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Fabry Disease Therapeutic covered in this report include Amicus therapeutics, Takeda, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company and GlaxoSmithKline plc, etc.
The global Fabry Disease Therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Global Fabry Disease Therapeutic market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Fabry Disease Therapeutic market, Segment by Type:
Enzyme Replacement Therapy
Alternative therapies
Global Fabry Disease Therapeutic market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Fabry Disease Therapeutic companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The global Fabry Disease Therapeutic market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Fabry Disease Therapeutic in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Fabry Disease Therapeutic market. Enzyme Replacement Therapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Alternative therapies segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Fabry Disease Therapeutic, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Fabry Disease Therapeutic market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Fabry Disease Therapeutic market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Fabry Disease Therapeutic sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Fabry Disease Therapeutic covered in this report include Amicus therapeutics, Takeda, Genzyme-Sanofi, Protalix, Sanofi-Aventis LLC, Novartis Pharmaceuticals, Pfizer, Bristol-Myers Squibb Company and GlaxoSmithKline plc, etc.
The global Fabry Disease Therapeutic market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Global Fabry Disease Therapeutic market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Fabry Disease Therapeutic market, Segment by Type:
Enzyme Replacement Therapy
Alternative therapies
Global Fabry Disease Therapeutic market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Fabry Disease Therapeutic companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Fabry Disease Therapeutic
1.1 Fabry Disease Therapeutic Market Overview
1.1.1 Fabry Disease Therapeutic Product Scope
1.1.2 Fabry Disease Therapeutic Market Status and Outlook
1.2 Global Fabry Disease Therapeutic Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Fabry Disease Therapeutic Market Size by Region (2018-2029)
1.4 Global Fabry Disease Therapeutic Historic Market Size by Region (2018-2023)
1.5 Global Fabry Disease Therapeutic Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Fabry Disease Therapeutic Market Size (2018-2029)
1.6.1 North America Fabry Disease Therapeutic Market Size (2018-2029)
1.6.2 Europe Fabry Disease Therapeutic Market Size (2018-2029)
1.6.3 Asia-Pacific Fabry Disease Therapeutic Market Size (2018-2029)
1.6.4 Latin America Fabry Disease Therapeutic Market Size (2018-2029)
1.6.5 Middle East & Africa Fabry Disease Therapeutic Market Size (2018-2029)
2 Fabry Disease Therapeutic Market by Type
2.1 Introduction
2.1.1 Enzyme Replacement Therapy
2.1.2 Alternative therapies
2.2 Global Fabry Disease Therapeutic Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Fabry Disease Therapeutic Historic Market Size by Type (2018-2023)
2.2.2 Global Fabry Disease Therapeutic Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Fabry Disease Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Fabry Disease Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Fabry Disease Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Fabry Disease Therapeutic Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Fabry Disease Therapeutic Revenue Breakdown by Type (2018-2029)
3 Fabry Disease Therapeutic Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Other
3.2 Global Fabry Disease Therapeutic Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Fabry Disease Therapeutic Historic Market Size by Application (2018-2023)
3.2.2 Global Fabry Disease Therapeutic Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Fabry Disease Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Fabry Disease Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Fabry Disease Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Fabry Disease Therapeutic Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Fabry Disease Therapeutic Revenue Breakdown by Application (2018-2029)
4 Fabry Disease Therapeutic Competition Analysis by Players
4.1 Global Fabry Disease Therapeutic Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Fabry Disease Therapeutic as of 2022)
4.3 Date of Key Players Enter into Fabry Disease Therapeutic Market
4.4 Global Top Players Fabry Disease Therapeutic Headquarters and Area Served
4.5 Key Players Fabry Disease Therapeutic Product Solution and Service
4.6 Competitive Status
4.6.1 Fabry Disease Therapeutic Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Amicus therapeutics
5.1.1 Amicus therapeutics Profile
5.1.2 Amicus therapeutics Main Business
5.1.3 Amicus therapeutics Fabry Disease Therapeutic Products, Services and Solutions
5.1.4 Amicus therapeutics Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.1.5 Amicus therapeutics Recent Developments
5.2 Takeda
5.2.1 Takeda Profile
5.2.2 Takeda Main Business
5.2.3 Takeda Fabry Disease Therapeutic Products, Services and Solutions
5.2.4 Takeda Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.2.5 Takeda Recent Developments
5.3 Genzyme-Sanofi
5.3.1 Genzyme-Sanofi Profile
5.3.2 Genzyme-Sanofi Main Business
5.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Products, Services and Solutions
5.3.4 Genzyme-Sanofi Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.3.5 Protalix Recent Developments
5.4 Protalix
5.4.1 Protalix Profile
5.4.2 Protalix Main Business
5.4.3 Protalix Fabry Disease Therapeutic Products, Services and Solutions
5.4.4 Protalix Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.4.5 Protalix Recent Developments
5.5 Sanofi-Aventis LLC
5.5.1 Sanofi-Aventis LLC Profile
5.5.2 Sanofi-Aventis LLC Main Business
5.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Products, Services and Solutions
5.5.4 Sanofi-Aventis LLC Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.5.5 Sanofi-Aventis LLC Recent Developments
5.6 Novartis Pharmaceuticals
5.6.1 Novartis Pharmaceuticals Profile
5.6.2 Novartis Pharmaceuticals Main Business
5.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Products, Services and Solutions
5.6.4 Novartis Pharmaceuticals Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Pharmaceuticals Recent Developments
5.7 Pfizer
5.7.1 Pfizer Profile
5.7.2 Pfizer Main Business
5.7.3 Pfizer Fabry Disease Therapeutic Products, Services and Solutions
5.7.4 Pfizer Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.7.5 Pfizer Recent Developments
5.8 Bristol-Myers Squibb Company
5.8.1 Bristol-Myers Squibb Company Profile
5.8.2 Bristol-Myers Squibb Company Main Business
5.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Products, Services and Solutions
5.8.4 Bristol-Myers Squibb Company Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.8.5 Bristol-Myers Squibb Company Recent Developments
5.9 GlaxoSmithKline plc
5.9.1 GlaxoSmithKline plc Profile
5.9.2 GlaxoSmithKline plc Main Business
5.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Products, Services and Solutions
5.9.4 GlaxoSmithKline plc Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.9.5 GlaxoSmithKline plc Recent Developments
5.10 Amgen Inc.
5.10.1 Amgen Inc. Profile
5.10.2 Amgen Inc. Main Business
5.10.3 Amgen Inc. Fabry Disease Therapeutic Products, Services and Solutions
5.10.4 Amgen Inc. Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.10.5 Amgen Inc. Recent Developments
5.11 Teva pharmaceutical Industries Ltd.
5.11.1 Teva pharmaceutical Industries Ltd. Profile
5.11.2 Teva pharmaceutical Industries Ltd. Main Business
5.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Products, Services and Solutions
5.11.4 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.11.5 Teva pharmaceutical Industries Ltd. Recent Developments
5.12 Merc & Co.
5.12.1 Merc & Co. Profile
5.12.2 Merc & Co. Main Business
5.12.3 Merc & Co. Fabry Disease Therapeutic Products, Services and Solutions
5.12.4 Merc & Co. Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.12.5 Merc & Co. Recent Developments
5.13 AbbVie Inc.
5.13.1 AbbVie Inc. Profile
5.13.2 AbbVie Inc. Main Business
5.13.3 AbbVie Inc. Fabry Disease Therapeutic Products, Services and Solutions
5.13.4 AbbVie Inc. Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.13.5 AbbVie Inc. Recent Developments
5.14 Takeda Pharmaceutical Co. Ltd.
5.14.1 Takeda Pharmaceutical Co. Ltd. Profile
5.14.2 Takeda Pharmaceutical Co. Ltd. Main Business
5.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Products, Services and Solutions
5.14.4 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.14.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
5.15 Green Cross Corp.
5.15.1 Green Cross Corp. Profile
5.15.2 Green Cross Corp. Main Business
5.15.3 Green Cross Corp. Fabry Disease Therapeutic Products, Services and Solutions
5.15.4 Green Cross Corp. Fabry Disease Therapeutic Revenue (US$ Million) & (2018-2023)
5.15.5 Green Cross Corp. Recent Developments
6 North America
6.1 North America Fabry Disease Therapeutic Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Fabry Disease Therapeutic Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Fabry Disease Therapeutic Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Fabry Disease Therapeutic Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Fabry Disease Therapeutic Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Fabry Disease Therapeutic Market Dynamics
11.1 Fabry Disease Therapeutic Industry Trends
11.2 Fabry Disease Therapeutic Market Drivers
11.3 Fabry Disease Therapeutic Market Challenges
11.4 Fabry Disease Therapeutic Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
